In this article, we discuss the top 5 healthcare stock picks of Timothy P. Lynch’s Stonepine Capital. If you want our detailed analysis of these stocks, go directly to Timothy P. Lynch’s Stonepine Capital Portfolio: Top 10 Healthcare Stocks.
5. Ovid Therapeutics Inc. (NASDAQ:OVID)
Stonepine Capital’s Stake Value: $10,930,000
Percentage of Stonepine Capital’s 13F Portfolio: 4.97%
Number of Hedge Fund Holders: 15
Ovid Therapeutics Inc. (NASDAQ:OVID) is a biopharmaceutical company with several unique medicines in its pipeline, meant for the treatment of rare neurological disorders. As of the third quarter, Lynch’s Stonepine Capital owns 3.25 million shares in Ovid Therapeutics Inc. (NASDAQ:OVID), worth $10.93 million, representing 4.97% of the firm’s total investments.
Ovid Therapeutics Inc. (NASDAQ:OVID) posted its Q3 results on November 10, with EPS for the quarter totaling -$0.17, beating estimates by $0.01.
Mark Lampert’s Biotechnology Value Fund / BVF Inc is the leading shareholder of Ovid Therapeutics Inc. (NASDAQ:OVID), with 6.63 million shares worth $22.28 million. Overall, 15 hedge funds in the Q3 database of Insider Monkey reported owning stakes in Ovid Therapeutics Inc. (NASDAQ:OVID), valued at $65 million.
4. Galapagos NV (NASDAQ:GLPG)
Stonepine Capital’s Stake Value: $12,848,000
Percentage of Stonepine Capital’s 13F Portfolio: 5.84%
Number of Hedge Fund Holders: 22
Galapagos NV (NASDAQ:GLPG) is a Belgian pharmaceutical research corporation that is engaged in the clinical stage of small molecule medicines aimed at treating multiple diseases including inflammation and fibrosis. Stonepine Capital owns 244,205 Galapagos NV (NASDAQ:GLPG) shares, worth $12.84 million as of the third quarter, representing 5.84% of the firm’s 13F portfolio.
Oleg Nodelman’s EcoR1 Capital is the largest stakeholder of Galapagos NV (NASDAQ:GLPG), with an $82 million stake in the company. Overall, 22 hedge funds reported owning stakes in Galapagos NV (NASDAQ:GLPG), worth $342.5 million as per Insider Monkey’s Q3 database.
3. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)
Stonepine Capital’s Stake Value: $19,222,000
Percentage of Stonepine Capital’s 13F Portfolio: 8.74%
Number of Hedge Fund Holders: 14
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), a company specializing in neurological therapies, is one of the top stock picks of Timothy Lynch’s Stonepine Capital from September this year. The investment firm owns 3.91 million shares in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), worth $19.2 million, representing 8.74% of Stonepine Capital’s Q3 investments.
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) was acquired on October 11 2021 by Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), and now operates as a subsidiary of the acquiring company.
On November 17, Northland analyst Carl Byrnes downgraded Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to Market Perform from Outperform, keeping an $8.50 price target on the shares to reflect the impending takeover by Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), which he expects to conclude by the end of 2021 or Q1 2022.
Steven Boyd’s Armistice Capital is the largest stakeholder of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS), with 4 million shares valued at $19.64 million. Overall, 14 hedge funds tracked by Insider Monkey were bullish on Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) as of Q3 2021, down from 15 funds in the preceding quarter.
2. CTI BioPharma Corp. (NASDAQ:CTIC)
Stonepine Capital’s Stake Value: $23,495,000
Percentage of Stonepine Capital’s 13F Portfolio: 10.69%
Number of Hedge Fund Holders: 11
CTI BioPharma Corp. (NASDAQ:CTIC) is a company investing in cell therapies for blood related cancers. After one of its products failed to deliver desired results for patients hospitalized due to COVID-19, Lake Street analyst Thomas Flaten on October 4 regarded the news as a buying opportunity and kept a Buy rating on the stock with a $15 price target.
CTI BioPharma Corp. (NASDAQ:CTIC) posted its Q3 results on November 12. EPS in the period came in at -$0.26, missing estimates by -$0.01. Samuel Isaly’s OrbiMed Advisors is one of the leading stakeholders of the company as of September 2021.
Out of the 867 hedge funds monitored by Insider Monkey as of the third quarter, 11 funds were bullish on CTI BioPharma Corp. (NASDAQ:CTIC), with stakes valued at $86.9 million. This is compared to 10 funds holding a position in CTI BioPharma Corp. (NASDAQ:CTIC) in Q2, with a total stake value of $74.3 million.
1. Amryt Pharma plc (NASDAQ:AMYT)
Stonepine Capital’s Stake Value: $69,882,000
Percentage of Stonepine Capital’s 13F Portfolio: 31.79%
Number of Hedge Fund Holders: 18
Amryt Pharma plc (NASDAQ:AMYT), a biopharmaceutical company targeting rare and debilitating diseases with its multitude of existing and developing treatments, is the largest holding in Stonepine Capital’s Q3 portfolio. Timothy Lynch, via Stonepine Capital, holds 5.8 million Amryt Pharma plc (NASDAQ:AMYT) shares, worth almost $70 million, representing 31.79% of the firm’s portfolio of Q3 securities.
Glenn Russell Dubin’s Highbridge Capital Management is one of the leading stakeholders of Amryt Pharma plc (NASDAQ:AMYT), holding a $19.75 million stake in the company. Overall, 18 hedge funds in the database of Insider Monkey were long Amryt Pharma plc (NASDAQ:AMYT) as of Q3 2021, up from 11 funds in the preceding quarter.
You can also take a look at 11 Best Autonomous Vehicle Stocks To Buy Now and Cathie Wood Stock Portfolio: 10 Newest Stock Picks This Year.
